Rejection therapy of prostate cancer patients who have been shut down can be overcome with treatment based on female hormones.
The study revealed the secret is to target specific tumor molecular estrogen response. Growth of prostate cancer usually associated with male hormones, namely androgen such as testosterone. But both men and women have a number of estrogen, female sex hormones.
Recent research shows that the biological pathways involving the estrogen can be used to fight prostate cancer. Estrogen binds specific receptors on the cell surface - biochemistry of molecules that trigger the effect when stimulated.
Research has shown that prostate tumors known to carry two estrogen receptors. One of them, estrogen receptor beta, which causes cancer cells to die when activated. Australian scientists are conducting research to develop a new drug that selectively target the estrogen receptor beta.
Professor Gail Risbridger, of Monash University in Victoria, who helped lead the study, said that these drugs not only inhibit the growth of prostate cancer, "but also kills cancer cells resistant to conventional treatment such as lack of androgen therapy, better known as castration therapy , and do so using different mechanisms by castration. "
This discovery was published in the journal Proceedings of the National Academy of Sciences.
0 comments:
Post a Comment